Using manufacturer-reported prescription pharmaceutical prices, we observe that the number of price increases has been reduced considerably since the release of the President’s Drug Pricing Blueprint, compared to the same time period in the year prior. Since the Blueprint’s release, there are 60% fewer brand name product price increases in 2018 compared to the same period in 2017, and 54% more brand and generic product price decreases combined.
Data point: Prescription Pharmaceutical Price Changes since the Release of the President’s Drug Pricing Blueprint
Publication Date
Files
Product Type
ASPE Data Point